[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ove Andersen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,72,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100607958","fisetin-supplementation-for-healthy-aging-100607958",false,"NCT07195318","Fisetin Supplementation for Healthy Aging","Low-dose Fisetin Supplementation for Healthy Aging - a Triple-blind, Randomized, Placebo-controlled Trial","Fisetin LOW","Inclusion Criteria:\n\n* Middle-aged or older adult (≥50 years),\n* Able to cooperate cognitively,\n* Able to read and understand Danish,\n\nExclusion Criteria:\n\n* Inability or unwillingness to take oral supplements,\n* Chronic or recent (within 30 days) use of other anti-aging supplements,\n* Chronic or recent (within 30 days) treatment with medications having anti-aging effects (e.g., metformin, rapamycin, semaglutide),\n* Chronic or recent (within 30 days) treatment with anti-inflammatory medications,\n* Chronic or recent (within 30 days) treatment with the medications that can interact negatively with fisetin,\n* Recent (within 14 days) vaccination,\n* Treatment with another investigational drug or other intervention within 1 year,\n* Active cancer or current cancer treatment,\n* Unstable or uncontrolled major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer, requiring regular monitoring at the hospital\n* Planned medical and surgical procedures during the study period,\n* Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules,\n* Presence of any condition that the investigator believes would put the participant at risk or would preclude the participant from successfully completing all aspects of the study",true,"ALL","50 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their \"anti-aging\" properties, claiming to target molecular and cellular \"hallmarks of aging\", such as chronic inflammation, oxidative stress, and cellular senescence. However, the overwhelming majority of these claims stem from preclinical studies in animal models (e.g., C. elegans, mice), and there is extremely limited evidence for beneficial effects, effective doses, or safety profiles of these supplements in humans. Moreover, the lack of strict regulations in the nutritional supplement industry leads to wide differences in the quality and in the actual content of active substances between supplements, which could impact both their efficacy and safety.\n\nThe investigators will conduct a clinical trial in healthy volunteers, who will receive supplementation with fisetin (100 mg) or placebo daily for 7 weeks. Participants will be examined at regular intervals during the study period. The investigators will then investigate whether fisetin supplementation is safe and evaluate its effect on measures of chronic inflammation, cellular senescence, aging, and general health.",[28],"Healthy",[30,31,32],"Chronic inflammation","Cellular senescence","Senotherapeutics","RECRUITING","2026-05-16",{"date":36,"type":37},"2026-05-19","ACTUAL",{"date":39,"type":37},"2025-09-24",{"date":41,"type":22},"2026-10-31",{"name":43,"class":44},"Ove Andersen","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100549278","phase-1-pilot-trial-of-fisetin-in-healthy-volunteers-and-older-patients-with-multimorbidity-100549278","NCT06431932","Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity","Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study","Fisetin HIGH","Healthy volunteers:\n\nInclusion Criteria:\n\n* Aged 20-35 years\n* suPAR levels \\\u003C3.5 ng\u002FmL (± 15% corresponding to assay variation)\n* Able to cooperate cognitively\n* Able to read and understand Danish\n* Women of childbearing potential must use effective contraception\n\nExclusion Criteria:\n\n* Body weight \\>100 kg\n* Inability to swallow pills\n* Pregnant and\u002For lactating\n* Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules\n* Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial\n* Presence of known chronic diagnosis\n* Active acute illness\n* Prescribed medication, except contraceptives\n* Previous cancer diagnosis or treatment\n* Use of senolytic and other \"anti-aging\" supplements\n\nOlder patients with multimorbidity:\n\nInclusion Criteria:\n\nAt screening #1 during hospital admission:\n\n* Acutely hospitalized medical patient\n* Age ≥65 years\n* suPAR \\>5 ng\u002FmL (± 15% corresponding to assay variation)\n* Multimorbidity (≥2 chronic diagnoses)\n* Able to cooperate cognitively\n* Able to read and understand Danish\n\nAt screening #2 28 days after hospital discharge:\n\n* suPAR \\>5 ng\u002FmL (± 15% corresponding to assay variation)\n\nExclusion Criteria:\n\nAt screening #1 during hospital admission:\n\n* Body weight \\>100 kg\n* Inability to swallow pills\n* Known human immunodeficiency virus infection, active hepatitis B or C infection, invasive fungal infection\n* Uncontrolled (as per clinical judgment) pleural\u002Fpericardial effusions or ascites\n* New\u002Factive invasive cancer except non-melanoma skin cancers\n* Active cancer treatment or disseminated cancer\n* Known condition associated with major immunodeficiency\n* Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules\n* Use of senolytic and other \"anti-aging\" supplements\n\nAt screening #2 28 days after hospital discharge:\n\n* Body weight \\>100 kg\n* CRP \\>30 mg\u002FL (± 15% corresponding to assay variation)\n* Inability to swallow pills\n* Presence of any condition, or abnormal routine biochemistry test, that the investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial\n* Unstable (as per clinical judgment) major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer\n* Estimated glomerular filtration rate (eGFR) \\\u003C15 ml\u002Fmin\u002F1.73 m2 or as per clinical judgment (e.g., risk of acute kidney injury)\n* Human immunodeficiency virus infection, known active hepatitis B or C infection, invasive fungal infection\n* Uncontrolled (as per clinical judgment) pleural\u002Fpericardial effusions or ascites\n* New\u002Factive invasive cancer except non-melanoma skin cancers\n* Active cancer treatment or disseminated cancer\n* Known condition associated with major immunodeficiency\n* Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules\n* Subjects taking strong inhibitors or inducers of CYP3A4 or as per clinical judgment\n* Subjects taking specified substrates with a narrow therapeutic range for CYP3A4 or as per clinical judgment\n* Subjects taking specified inhibitors, inducers, or substrates of CYP2D6, CYP2C9, or CYP2C8, or as per clinical judgment\n* Subjects regularly using drug classes or specific medications or as per clinical judgment\n* Use of senolytic and other \"anti-aging\" supplements","20 Years",{"count":56,"type":22},60,[58,59],"PHASE1","PHASE2","The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.\n\nWe will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.",[62,28],"Multimorbidity",[64,65,30],"Senolytic","Pharmacokinetics",{"date":36,"type":37},{"date":68,"type":37},"2026-03-24",{"date":70,"type":22},"2028-12-31",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100631478","methods-for-nutrition-inflammation-kidney-function-aging-body-composition-and-hydration-among-older-patients-100631478","NCT07501195","Methods for Nutrition, Inflammation, Kidney Function, Aging, Body Composition, and Hydration Among Older Patients","Methods for Assessing Nutrition, Inflammation, Kidney Function, Aging, Body Composition, and Hydration Among Older Patients - An Observational Study (MIKADO)","MIKADO","Inclusion Criteria:\n\n* 65 years or older (group 1, 4 and 5)\n* 90 years or older (group 3)\n* Acute admission (group 1, 2)\n* Cognitively able to cooperate (group 1)\n* Able to read and speak Danish (group 1, 2, 3, 4, 5, 6)\n* BMI ≥ 35 kg\u002Fm2 (group 4)\n* Prednisolon treatment for COPD (≥ 37,5 mg daily) (group 5)\n* Amputation(s) of crus or femur (non-traumatic) (group 6)\n\nExclusion Criteria:\n\n* Isolation (group 1, 2, 3, 4, 5, 6)\n* Terminal treatment (group 1, 2, 3, 4, 5, 6)\n* Suicidal (group 1, 2, 3, 4, 5, 6)\n* Active Immune suppressing treatment (group 2, 3, 4, 5, 6)\n* Oedemas (group 2, 3, 4, 5, 6)\n* In active treatment for cancer (group 2, 3, 4, 5, 6)","65 Years",{"count":82,"type":22},500,"OBSERVATIONAL","The goal of this observational study, is to improve the diagnostic assessment method of malnutrition and kidney diseases, amongst hospitalized and low priority patients, by evaluating modern methodology and biomarkers, with regards to an estimate of the nutritional status and kidney diseases, against current gold standards, and also investigate how body composition, hydration, inflammation and age affect the assessments.",[86,87,88],"Malnutrition Elderly","Kidney Diseases","Dehydration","2026-03-26",{"date":91,"type":37},"2026-03-30",{"date":93,"type":37},"2026-03-01",{"date":95,"type":22},"2035-09",{"name":43,"class":44},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":18,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100499888","deep-venous-thrombosis-and-long-term-complications-100499888","NCT05789108","Deep Venous Thrombosis and Long Term Complications","Deep Venous Thrombosis and Risk of Long Term Complications in Acutely Admitted Patients","Inclusion Criteria:\n\n* 18 years or above\n* First time lower extremity DVT\n* Hospitalized at the Emergency Department\n\nExclusion Criteria:\n\n* Patients without a Danish social security number\n* Terminal patients\n* Patients who do not understand or speak Danish","18 Years",{"count":106,"type":22},178,[25],"In this cohort study, the investigators will investigate the concentration of biomarkers, e.g., inflammatory, anti-inflammatory, immunological, senescent, biochemical ratio-calculations, blood cell type, and and long term complications with a 2-year follow-up in patients with first time lower extremity deep venous thrombosis",[110],"DVT of Legs",[112,113,114,115,116,117],"DVT","aging","inflammation","anti-inflammation","immune system","PTS","2026-02-19",{"date":120,"type":37},"2026-02-23",{"date":122,"type":37},"2023-03-14",{"date":124,"type":22},"2029-09-01",{"name":43,"class":44},""]